The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | Phase I trial of OBX-115, an IL2-sparing TIL, in pre-treated metastatic melanoma
Rodabe Navroze Amaria, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the Phase I study (NCT05470283) evaluating OBX-115, a membrane-bound IL15-expressing autologous engineered tumor-infiltrating lymphocyte (TIL), in immune checkpoint inhibitor (ICI)-resistant metastatic melanoma. Durable responses were observed, indicating clinical benefit without high-dose IL2. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role – Bristol-Myers Squibb/Medarex; Erasca, Inc; Iovance Biotherapeutics; Novartis; Obsidian Therapeutics
Research Funding – Bristol-Myers Squibb (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst)
